Biobank Japan

Sep 20, 2024 | nature.com | Tatsuhiko Naito |Shinichi Namba |Kyuto Sonehara |Ken Suzuki |Biobank Japan |Koichi Matsuda | +2 more

AbstractAlthough polygenic risk scores (PRSs) are expected to be helpful in precision medicine, it remains unclear whether high-PRS groups are more likely to benefit from preventive interventions for diseases. Recent methodological advancements enable us to predict treatment effects at the individual level. We employed causal forest to explore the relationship between PRSs and individual risk of diseases associated with certain environmental factors.

Jun 17, 2024 | medrxiv.org | Yoichiro Kamatani |Biobank Japan |Naoki Kojima |Masaru Koido

Y.K. holds stock of Staten Co., Ltd. This research was supported by the Ministry of Education, Culture, Sports, Sciences and Technology (MEXT) of the Japanese government and the Japan Agency for Medical Research and Development (AMED) under grant nos. JP18km0605001/ JP23tm0624002 (the BioBank Japan project), JP223fa627011 (Y.K.), and JP23tm0524003 (Y.K.). I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.